Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) received a Nasdaq written notification on Feb 9, 2026, for failing to meet the $1.00 minimum bid price under Nasdaq Listing Rule 5550(a)(2).

The company has a 180-calendar-day compliance period until Aug 10, 2026, to regain compliance by achieving a $1.00 closing bid for ten consecutive business days; shares continue to trade on Nasdaq during this period.

Positive

• 180-day compliance period granted through Aug 10, 2026
• Ordinary shares remain listed and continue trading on Nasdaq
• Company committed to monitoring share price and evaluating cure options

Negative

• Closing bid price below $1.00 for 30 consecutive business days
• Risk of delisting if compliance not regained within allotted period(s)
• May need a reverse share split to cure the minimum bid deficiency

Key Figures

Minimum bid price: $1.00 per share Non-compliance period: 30 consecutive business days Initial compliance period: 180 calendar days +3 more

6 metrics

Minimum bid price $1.00 per share Nasdaq Listing Rule 5550(a)(2) requirement

Non-compliance period 30 consecutive business days Closing bid below $1.00 threshold

Initial compliance period 180 calendar days Compliance window ending August 10, 2026

Compliance deadline August 10, 2026 End of initial Nasdaq compliance period

Required bid duration 10 consecutive business days Minimum time bid must be ≥ $1.00

Potential extension Second 180-day period Additional time if other listing standards met

Market Reality Check

Price: $0.5889 Vol: Volume 632,201 is below t...

low vol

$0.5889 Last Close

Volume Volume 632,201 is below the 20-day average of 1,449,241 (relative volume 0.44x). low

Technical Shares at $0.613 are trading below the $0.99 200-day moving average.

Peers on Argus

IINN was down 3.71% with mixed moves in peers: MYO (-4.24%), RBOT (-4.12%), MODD...

IINN was down 3.71% with mixed moves in peers: MYO (-4.24%), RBOT (-4.12%), MODD (-0.87%) declined, while ECOR (+1.3%) and NMTC (+0.38%) rose, pointing to stock-specific pressures.

Historical Context

5 past events · Latest: Feb 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Commercial approval win	Positive	-5.6%	Clalit vendor approval enabling ART100 deployment across large HMO network.
Feb 05	Dilutive financing	Negative	-6.5%	Registered direct offering and concurrent warrant placement raising $4.75M.
Feb 03	Product validation	Positive	+4.9%	HYLA standalone blood sensor validation targeting heart-lung surgery market.
Jan 29	Clinical adoption	Positive	-0.1%	ART100 completed evaluation and entered routine workflow at top U.S. center.
Jan 21	Order progression	Positive	-4.6%	Governmental validation advanced for $22.5M and $27M binding purchase orders.

Pattern Detected

Recent positive commercial and clinical updates often saw flat or negative price reactions, while financing news aligned with downside moves.

Recent Company History

Over recent weeks, Inspira reported multiple commercial and clinical milestones, including ART100 clinical adoption, HYLA sensor validation, and progress on $49.5M in binding purchase orders. Despite this, shares fell after the Clalit vendor approval (-5.59%) and governmental validation update (-4.57%). Financing events, such as the $4.75M registered direct offering with warrants (-6.49%), also pressured the stock. The current Nasdaq minimum bid price notice follows this stretch of mixed fundamental news and predominantly negative price reactions.

Regulatory & Risk Context

Active S-3 Shelf · $75,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-25

$75,000,000 registered capacity

An effective Form F-3 shelf filed on Nov 25, 2025 allows Inspira to offer up to $75,000,000 of ordinary shares, warrants and units from time to time, indicating capacity for future capital raises that could impact existing shareholders.

Market Pulse Summary

This announcement formally discloses that IINN fell out of compliance with Nasdaq’s $1.00 minimum bi...

Analysis

This announcement formally discloses that IINN fell out of compliance with Nasdaq’s $1.00 minimum bid price rule after 30 consecutive sub-threshold closes, triggering a 180-day cure period to August 10, 2026. It follows recent commercial wins and financings that produced mixed share reactions. Investors may watch whether the bid holds at or above $1.00 for at least 10 consecutive days, and how any use of the $75,000,000 shelf intersects with compliance efforts.

Key Terms

minimum bid price requirement, nasdaq capital market, deficiency notification, reverse share split

4 terms

minimum bid price requirement regulatory

"it is not currently in compliance with the minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

nasdaq capital market regulatory

"continue to trade on The Nasdaq Capital Market under the symbol “IINN.”"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

deficiency notification regulatory

"requires prompt disclosure of receipt of a deficiency notification."

A deficiency notification is a formal notice from a regulator, exchange, or reviewer pointing out missing, unclear, or inadequate information in a company’s filing or application. It matters to investors because it can delay approvals, listings, fundraising or product launches and signal compliance or disclosure problems; think of it as a teacher returning a homework sheet with items circled that must be fixed before the work is accepted.

reverse share split financial

"including by effectuating a revere share split, if necessary."

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

AI-generated analysis. Not financial advice.

RA'ANANA, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on February 9, 2026, notifying the Company that it is not currently in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s ordinary shares (“Ordinary Shares”) was below $1.00 per share for the last 30 consecutive business days.

The Notification Letter has no immediate effect on the listing or trading of the Company’s Ordinary Shares, which will continue to trade on The Nasdaq Capital Market under the symbol “IINN.”

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a compliance period of 180 calendar days, or until August 10, 2026 (the “Compliance Period”), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s Ordinary Shares must be at least $1.00 per share for a minimum of ten consecutive business days during the Compliance Period.

If the Company does not regain compliance by August 10, 2026, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effectuating a revere share split, if necessary. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting.

The Company intends to monitor the closing bid price of its Ordinary Shares between now and August 10, 2026, and intends to consider available options to cure the deficiency regain compliance with the Nasdaq minimum bid price requirement within the Compliance Period.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About Inspira Technologies
 Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.

Forward-Looking Statements
 This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ability to regain compliance with the Nasdaq minimum bid price requirement within the applicable Compliance Period, its intention to monitor the trading price of its Ordinary Shares, and its consideration of available options to regain compliance with Nasdaq listing requirements. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.

Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485

FAQ

What did Inspira Technologies (IINN) receive from Nasdaq on Feb 9, 2026?

The company received a written notification for failing to meet the $1.00 minimum bid. According to the company, the closing bid was below $1.00 for 30 consecutive business days, triggering the Nasdaq deficiency notice.

How long is Inspira Technologies (IINN) given to regain Nasdaq compliance?

Inspira has a 180-calendar-day compliance period ending on Aug 10, 2026. According to the company, this period requires a $1.00 closing bid for ten consecutive business days to regain compliance.

Will Inspira Technologies (IINN) be delisted immediately after the Nasdaq notice?

No, delisting is not immediate; shares continue to trade on Nasdaq. According to the company, delisting would occur only if compliance isn’t regained within the allotted compliance period(s).

What must Inspira Technologies (IINN) do to regain compliance with Nasdaq?

The company must achieve a closing bid of at least $1.00 for ten consecutive business days during the compliance period. According to the company, alternative cures may include a reverse share split.

If Inspira Technologies (IINN) fails the first compliance period, what happens next?

The company may be eligible for a second 180-day period if it meets other listing standards and notifies Nasdaq. According to the company, meeting market value and other initial listing criteria is required.